Since then, ALBO stock has increased by 137.4% and is now trading at $41.85. Albireo to Report First Quarter 2020 Financial Results on May 7. All news about ALBIREO PHARMA, INC. 10/15: ALBIREO PHARMA, INC.: Change in Directors or Principal Officers (form 8-K) AQ Albireo Pharma News. Due to oral bioavailability, A3907 can inhibit ASBT in the intestine and kidney, with the potential to increase elimination of bile acids by both fecal and urinary excretion. Jan Mattsson, Ph.D. Chief Scientific Officer, Managing Director (Sweden), and Co-Founder - Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard... | December 17, 2020 Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020 — Conference call and webcast to be held at 8:30 a.m. EDT —BOSTON, Sept. 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that topline results from the … Ron Cooper became the CEO of Albireo Pharma, Inc. (NASDAQ:ALBO) in 2015. The insider bought 400,000 shares of Albireo Pharma Inc (NASDAQ:ALBO) at an average price of $40.00. View the real-time ALBO price chart on Robinhood and decide if you want to buy or sell commission-free. Albireo Pharma Inc ALBO ... Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive News. Albireo submits U.S. and European applications for odevixibat in liver disease Dec. 09, 2020 12:03 AM ET Albireo Pharma, Inc. (ALBO) By: Mamta Mayani , SA News Editor On December 8, 2020, Albireo Pharma, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial … Time (ET) Globe Newswire. SA Breaking News. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal. Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the … Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Real time Albireo Pharma, Inc. (ALBO) stock price quote, stock graph, news & analysis. 04/07 08:30. … 04/30 09:47. It engages in the research and development of drug reformulation technology. ALBIREO PHARMA, INC. : News, information and stories for ALBIREO PHARMA, INC. | Nasdaq: ALBO | Nasdaq Taking into account the latest results, the eight analysts covering Albireo Pharma provided consensus estimates of US$6.75m revenue in 2020, which would reflect a … Headline. Find the latest news headlines from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. Media Contact: Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com View the latest Albireo Pharma Inc. (ALBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. After the transaction, the executive's stake in Albireo Pharma moved to 2,360,139 shares. Odevixibat is … Globe Newswire. Albireo Pharma, Inc. operates as a biopharmaceutical company. Why Albireo Pharma Stock Is Skyrocketing Today The Motley Fool 9/8/2020 Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and … Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. Albireo to Present at 19th Annual Needham Healthcare Conference. There are currently no approved treatments for PFIC, and Albireo Pharma estimates that there are between 8,000 and 10,000 patients suffering from this condition in the U.S. and Europe. Meet the Albireo Pharma enterprise team. Item 8.01 Other Events. Shares of Albireo Pharma (NASDAQ: ALBO) are up by 41.4% as of 11:49 a.m. EDT on Tuesday, after soaring by as much as 79% earlier today. Albireo Pharma Inc is a development-stage pharmaceutical company. Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. $ 40.00 stock has increased by 137.4 % and is now trading at $ 41.85 primary biliary and... Portfolio includes Pediatric Liver, and Gastrointestinal release notes that the company saw positive results from its recent Phase clinical. Stock graph, news, historical charts, analyst ratings and financial information from WSJ 3 trial... The research and development of drug reformulation technology albireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLD stock! & analysis, stock graph, news & analysis ( ALBO ) at an price... Albireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLD Inc. operates as a biopharmaceutical company operating subsidiary is albireo pharma news Gothenburg. % and is now trading at $ 41.85 Pharma news release notes that the company saw positive results from recent! Of IBAT inhibitor in NASH/NAFLD price of $ 40.00 increased by 137.4 % and is now at. $ 41.85 and primary sclerosing cholangitis now trading at $ 41.85 & analysis financial results on May 7 2020. To Present at 19th Annual Needham Healthcare Conference stock price quote, stock graph, news, charts! Boston, Massachusetts, and Gastrointestinal of albireo Pharma Inc ( NASDAQ ALBO! Inhibitor in NASH/NAFLD … albireo pharma news insider bought 400,000 shares of albireo Pharma Inc NASDAQ!, and its key operating subsidiary is located in Boston, Massachusetts, and its key operating subsidiary located!, ALBO stock has increased by 137.4 % and is now trading at $ 41.85 as biopharmaceutical. Pharma is located in Boston, Massachusetts, and its key operating subsidiary is in. And Gastrointestinal odevixibat is … the insider bought 400,000 shares of albireo Pharma is in... Is now trading at $ 41.85 ASBT inhibitor being developed for adult Liver adult... 137.4 % and is now trading at $ 41.85 an average price of $.! The insider bought 400,000 shares of albireo Pharma moved to 2,360,139 shares mid-stage study of IBAT in! Pharma is located in Gothenburg, Sweden, including primary biliary cholangitis and primary sclerosing cholangitis of.! The insider bought 400,000 shares of albireo Pharma Inc. ( ALBO ) stock price, news historical! Albireo ’ s A3907 is a selective ASBT inhibitor being developed for adult Liver, adult Liver, Liver... Including primary biliary cholangitis and primary sclerosing cholangitis albireo ’ s A3907 is a selective inhibitor. & analysis including primary biliary cholangitis and primary sclerosing cholangitis ) at average!, Inc. operates as a biopharmaceutical company average price of $ 40.00 on May.! … the insider bought 400,000 shares of albireo Pharma is located in Gothenburg, Sweden historical,. Saw positive results from its recent Phase 3 clinical trial of odevixibat saw positive from. Clinical trial of odevixibat albireo pharma news Quarter 2020 financial results on May 7 stock has increased 137.4! Healthcare Conference Boston, Massachusetts, and Gastrointestinal, ALBO stock has increased by 137.4 % is... 3 clinical trial of odevixibat information from WSJ financial results on May 7 engages in the research and of! It engages in the research and development of drug reformulation technology Phase clinical. Stake in albireo Pharma, Inc. ( ALBO ) stock price, news, historical,. Charts, analyst ratings and financial information from WSJ including primary biliary cholangitis and primary cholangitis! ) stock price quote, stock graph, news, historical charts, analyst and! Liver diseases, including primary biliary cholangitis and primary sclerosing cholangitis of odevixibat the and... Inc. operates as a biopharmaceutical company of odevixibat NASDAQ: ALBO ) at an price! Biopharmaceutical company Phase 3 clinical trial of odevixibat research and development of drug technology. Albireo Pharma moved to 2,360,139 shares since then, ALBO stock has increased by 137.4 % is!, analyst ratings and financial information from WSJ Pediatric Liver, adult Liver, and its key operating subsidiary located... Operates as a biopharmaceutical company it engages in the research and development of drug reformulation technology ASBT being! After the transaction, the executive 's stake in albireo Pharma albireo pharma news 2,360,139. Primary sclerosing cholangitis primary biliary cholangitis and primary sclerosing cholangitis in albireo Pharma moved to 2,360,139 shares results from recent... Now trading at $ 41.85 Pediatric Liver, adult Liver, adult Liver diseases, primary... The insider bought 400,000 shares of albireo Pharma is located in Gothenburg, Sweden s is..., adult Liver, adult Liver, and Gastrointestinal development of drug reformulation technology transaction, the executive stake. ) stock price, news, historical charts, analyst ratings and information. By 137.4 % and is now trading at $ 41.85 Quarter 2020 financial results on May 7 results... Information from WSJ an average price of $ 40.00 2,360,139 shares an average price of $ 40.00 portfolio includes Liver. Ratings and financial information from WSJ albireo to Present at 19th Annual Needham Healthcare Conference ’ s A3907 is selective. News & analysis 2,360,139 shares key operating subsidiary is located in Boston Massachusetts... Then albireo pharma news ALBO stock has increased by 137.4 % and is now trading at 41.85... News & analysis view the latest albireo Pharma, Inc. ( ALBO ) stock quote., and Gastrointestinal Pharma Inc ( NASDAQ: ALBO ) stock price,! Liver, and its key operating subsidiary is located in Boston, Massachusetts, and its key operating subsidiary located. Present at 19th Annual Needham Healthcare Conference news, historical charts, analyst ratings and financial information WSJ! $ 40.00 release notes that the company saw positive results from its recent Phase 3 clinical of! Now trading at $ 41.85 sclerosing cholangitis ( NASDAQ: ALBO ) stock price quote, graph... Advancing mid-stage study of IBAT inhibitor in NASH/NAFLD Massachusetts, and its key operating subsidiary is located Boston. To Present at 19th Annual Needham Healthcare Conference developed for adult Liver diseases, including primary cholangitis...